Okuvision GmbH Initiates Multi-Center, Post-Market Study

Okuvision GmbH Initiates Multi-Center, Post-Market Study PR Newswire REUTLINGEN, Germany, Nov. 8, 2012 -- 100 Patients across Europe to Receive Transcorneal Electrical Stimulation (TES) REUTLINGEN, Germany, Nov. 8, 2012 /PRNewswire/ -- Okuvision GmbH, an innovator in the field of transcorneal electrical stimulation (TES) therapy for early and intermediate stage retinitis pigmentosa (RP) patients, today announced the start of a multi-center, post-market study for the company's CE marked OkuStim® treatment. OkuStim represents an advance in the treatment of RP, providing patients with a clinical option that has been shown to delay the progress of RP-related blindness. The new, post-market study, called TESOLA, is currently underway and enrolling patients at six sites in Germany, Norway and Denmark. Four additional sites in Germany and the UK are working with their internal regulatory boards to gain approval to become active study sites within the coming weeks. "Medical technology is progressing at an ever-increasing pace, and with developments such as OkuStim TES, patients with RP are gaining new hope for delaying and possibly preventing blindness from the disease," said Professor Florian Gekeler, lead clinical trial investigator and consultant at the Centre for Ophthalmology of the University of Tuebingen, Germany.